Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BioStar Capital is a venture capital firm established in 2005 by Dr. Louis A. Cannon, a prominent figure in cardiology. Headquartered in the United States, the firm specializes in transformative medical technologies, particularly in the fields of cardiology, orthopedics, and robotics. With a disciplined investment approach, BioStar Capital manages five venture capital funds and actively seeks both early- and late-stage investment opportunities. The firm is distinguished by its unique composition of healthcare clinicians, executives, medical thought leaders, and financial professionals, which enhances its investment process and decision-making capabilities.
Since its inception, BioStar Capital has built a reputation for identifying and supporting innovative solutions that address unmet patient needs. The firm’s leadership, particularly Dr. Cannon, brings extensive experience and insight into the healthcare sector, allowing BioStar to navigate the complexities of medical technology investments effectively. The firm’s geographic presence spans the United States, with offices located in Michigan and Ohio, enabling it to tap into a diverse range of healthcare innovations across the country.
BioStar Capital's investment focus is centered on innovation in medical technology that addresses critical unmet patient needs, especially in cardiovascular and orthopedic care. The firm actively seeks opportunities in sectors such as healthcare, biotech, and robotics, with a particular emphasis on smart devices, minimally invasive solutions, and technologies that enhance patient access and reduce healthcare costs. BioStar Capital evaluates potential investments based on several criteria, including commercial relevance, potential buyers, capital requirements, intellectual property status, clinical impact, and opportunities for value addition.
The firm is particularly interested in technologies that can transform patient care, such as robotic surgical instruments, outpatient-center technologies, and cost-reduction innovations. By focusing on these areas, BioStar Capital aims to support startups that are pioneering advancements in medical technology, ultimately improving patient outcomes and healthcare delivery.
BioStar Capital has a robust portfolio that includes several notable exits in the medical technology space. The firm has invested in transformative solutions such as Transcatheter renal denervation for hypertension, Pulsatile Intravascular Lithotripsy (PIVL) for treating calcified arteries, and passive implants for pulmonary hypertension. Other significant technologies include catheter-based nerve sensing and ablation procedures, pulsed field ablation (PFA) for ventricular tachycardia (VT), and robotically manufactured polymer heart valves.
Additionally, BioStar Capital has backed innovations in robotic microsurgery using NanoWrist instruments, endovascular therapies for abdominal aortic aneurysms (AAA), and handheld devices for dry eye disease. Their portfolio also features bioresorbable polymer technologies for vascular applications and long-term continuous glucose monitoring systems for diabetes management. The firm’s strategic investments reflect its commitment to advancing medical technology that significantly impacts patient care.
Dr. Louis A. Cannon - Founder and Managing Partner. Dr. Cannon is a recognized leader in cardiology with extensive experience in medical technology investments.
To pitch BioStar Capital, founders should email info@biostarcapital.com. It is recommended to include a detailed overview of the business, highlighting the technology, market potential, and how it addresses unmet patient needs in the healthcare sector.
BioStar Capital invests across multiple stages, including Seed, Series A, Series B, and Growth Equity. This diverse stage focus allows them to support companies at various points in their development, from early-stage innovations to more established growth opportunities.
Founders interested in pitching to BioStar Capital can reach out via email at info@biostarcapital.com. It is advisable to provide a clear overview of the business, including the technology, market potential, and how it addresses unmet patient needs in the healthcare sector.
BioStar Capital primarily focuses on healthcare, biotech, and robotics sectors. Their investment strategy emphasizes transformative medical technologies that improve patient care, particularly in cardiology and orthopedics.
While specific check sizes are not detailed in the source material, BioStar Capital invests in both early- and late-stage opportunities, which typically suggests a range that accommodates various funding needs depending on the stage of the company.
BioStar Capital is based in the United States, with offices in Michigan and Ohio. This geographic focus allows them to engage with a wide array of healthcare innovations across the country.
The application process involves reaching out via email at info@biostarcapital.com. Founders should prepare a comprehensive pitch that outlines their business model, technology, and market strategy.
BioStar Capital leverages its team of healthcare clinicians and financial professionals to provide strategic guidance and support to portfolio companies. This includes mentorship and access to a network of medical thought leaders, enhancing the potential for successful outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.